Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of eculizumab in refractory generalized myasthenia gravis
NL-OMON40159Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized myasthenia gravis (gMG) comparing Eculizumab with Placebo (2 arms). Primary endpoint: Change from baseline in MG-ADL total score at Week 26. Started Mar 2015; status: active, not recruiting.
02
Drugs
eculizumab
03
Conditions
generalized myasthenia gravis (gMG)
Beyond the preview
Go deeper on NL-OMON40159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40159.